Finance · GA Daily Post
Samsung Bioepis deal puts Teva Pharmaceutical Industries in focus Teva Pharmaceutical Industries (NYSE:TEVA) has moved higher up investor watchlists after a new global agreement with Samsung Bioepis covering up to six biosimilar candidates, including respiratory and immunology assets. The fresh tie-up extends an existing relationship that already includes EPYSQLI in the U.S. and OPUVIZ in Canada. It also lands just days after FDA approval of DEGEVMA, adding another biosimilar pillar to Teva’s toolkit.
Recent moves in Teva Pharmaceutical Industries tell a mixed story. The share price slipped around 1% over the past day and 2% over the week, yet logged an 18.6% 3‐month share price return and a 1‐year total shareholder return close to 96%. This suggests momentum has been building as investors react to new biosimilar approvals, an expanded Samsung Bioepis collaboration, and leadership changes at TAPI.
Spot opportunities that follow similar biosimilar and healthcare momentum by scanning our curated list of 34 healthcare AI stocks aligned with themes investors are watching around Teva Pharmaceutical Industries. Bulls point to Teva Pharmaceutical Industries’ biosimilar pipeline and recent approvals, while bears flag past volatility and execution risk. The recent surge in returns now raises a simple issue: Do current valuation levels still look reasonable?
Most Popular Narrative: 7% Undervalued On the narrative view, Teva Pharmaceutical Industries carries an implied fair value of $42 per share compared with a last close of $39.13, pointing to a modest valuation gap that hinges on execution in higher margin therapies and biosimilars. The shift in Teva Pharmaceutical Industries toward higher value branded CNS drugs such as AUSTEDO, AJOVY and UZEDY is increasing the share of revenue tied to products that currently carry higher gross margins. Management links this shift to the goal of non GAAP operating margins of 30% and a higher EBITDA contribution over time.
See why 5 investors see Teva Pharmaceutical Industries as 7% undervalued . Result: Fair Value of $42 (UNDERVALUED) Still, Teva Pharmaceutical Industries faces clear pressure points, including execution risk around its crowded launch queue and the possibility that higher margin targets will be difficult to sustain. Find out about the key risks to this Teva Pharmaceutical Industries narrative .
Another View on Teva Pharmaceutical Industries’ Valuation On the multiples side, Teva Pharmaceutical Industries looks expensive. The stock trades on a P/E of 64.6x, compared with about 15.1x for the wider US pharmaceuticals group and 17.8x for closer peers. That gap leaves less room for error if the growth story stumbles, so how comfortable are you paying up for it?
See what the numbers say about this price in our valuation breakdown by checking the See what the numbers say about this price — find out in our valuation breakdown. right after this. NYSE:TEVA P/E Ratio as at Oct 2026 Next Steps Mixed signals around Teva Pharmaceutical Industries can be confusing, so move quickly, review the data, and weigh both sides through the 3 key rewards and 3 important warning signs . Looking for more investment ideas beyond Teva Pharmaceutical Industries?
If you like what is happening around Teva Pharmaceutical Industries, do not stop here. Use focused stock lists to keep finding fresh opportunities that fit your style. Target resilient cash generators by scanning a list of solid balance sheet and fundamentals (25 results) that can help anchor a portfolio when sentiment swings.
Hunt for mispriced potential with a curated 19 high quality undiscovered gems list that many investors may not be watching yet. Protect your downside first by filtering for 31 resilient stocks with low risk scores that prioritise steadier fundamentals and calmer price moves. This article by Simply Wall St is general in nature.
We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Valuation is complex, but we're here to simplify it.
Discover if Teva Pharmaceutical Industries might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition. Access Free Analysis Have feedback on this article? Concerned about the content?
Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Source: Simply Wall Street
